Forty Pelibuey × Kathdin lambs (35.5 ± 0.4 kg) were used in a 56-day feeding experiment to assess the effects of feeding different levels of chromium-enriched live yeast (Cr-YC) on growth performance, dietary energetics, carcass traits and visceral organ mass. The Cr-YC source contained 5.5 × 109 colony forming units (CFU) and 0.40 mg of Cr per gram. Treatments consisted of a dry rolled corn-based finishing diet supplemented with 0, 1, 2 or 3 g Cr-YC/lamb.day. Total daily dosages were: 5.5 × 109 CFU and 0.4 mg; 1.1 × 1010 CFU and 0.8 mg Cr, and 1.65 × 1010 CFU and 1.2 mg Cr for supplementation levels of 1, 2 or 3 g Cr-YC/lamb.day, respectively. There were no treatments effects on dry matter intake. As the level of Cr-YC supplementation increased, average daily gain, gain to feed and dietary net energy were linearly increased, and observed/expected dry matter intake was linearly decreased. Chromium-enriched live yeast supplementation increased empty bodyweight (EBW), gastrointestinal fill and full viscera weight, but did not influence organ weights as a proportion of EBW (g/kg EBW). Cr-YC level did not affect carcass length, backfat thickness, kidney, pelvic and heart fat or body wall thickness, but increased hot carcass weight and longissimus muscle area. In general, treatment effects on percentage yield of wholesale cuts (tissue weight as a percentage of cold carcass weight) were small. However, Cr-YC decreased percentage flank. Chromium-enriched yeast supplementation enhances growth rate, longissimus muscle area, and dietary energetic efficiency in finishing feedlot lambs.

Fatty Acid Amide Hydrolase (FAAH) is one of the main enzymes responsible for endocannabinoid metabolism. Inhibition of FAAH increases endogenous levels of fatty acid ethanolamides such as anandamide (AEA) and thus consitutes an indirect strategy that can be used to modulate endocannabinoid tone. In the present work, we present a three-dimensional quantitative structure-activity relationships/comparative molecular similarity indices analysis (3D-QSAR/CoMSIA) study on a series of 90 reported irreversible inhibitors of FAAH sharing a piperazine-carboxamide scaffold. The model obtained was extensively validated (q2 = 0.734; r2 = 0.966; r2m = 0.723). Finally, based on the information derived from the contour maps we designed a series of 10 new compounds with high predicted FAAH inhibition (predicted pIC50 of the best-proposed compounds = 12.196; 12.416).

Fatty Acid Amide Hydrolase (FAAH) is one of the enzymes responsible of endocannabinoids metabolism. The inhibition of FAAH is a useful and indirect strategy to raise endogenous cannabinoid concentrations, which would be useful for the treatment of various pathological processes in which cannabinoid concentrations are lowered. In the present work, we present an extensive 3D-QSAR/CoMSIA study on a series of 90 irreversible inhibitors of FAAH of pyrimidinyl-piperazine-carboxamide structure. The final model obtained was extensively validated (q2 = 0.734; r2test = 0.966; r2m = 0.723), and based on the information derived from the contour maps we reported a series of 10 new compounds designed as powerful FAAH inhibitors (pIC50 of the best-proposed compounds = 12.196; 12.416).